http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 08:32:21 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/AngioDynamics+gets+FDA+approval+to+study+NanoKnife+for+BPH+treatment/26657354.html <p>AngioDynamics, Inc. (NASDAQ: ANGO) announced that the U.S. Food and Drug Administration has approved its Investigational Device Exemption application to begin the RELIEF feasibility study, which will evaluate the company's NanoKnife System as a treatment for lower urinary tract symptoms in men with benign prostatic hyperplasia (BPH).</p><p>The NanoKnife System uses irreversible electroporation (IRE), a non-thermal ablation technology that delivers high-voltage electrical pulses to destroy targeted tissue. The device is currently cleared in the United States for the surgical ablation of soft tissue, including prostate tissue, but its use for BPH remains investigational.</p><p>The RELIEF study is a prospective, single-arm trial that http://www.streetinsider.com/Corporate+News/AngioDynamics+gets+FDA+approval+to+study+NanoKnife+for+BPH+treatment/26657354.html Wed, 17 Jun 2026 08:32:21 -0400 ANGO http://www.streetinsider.com/FDA/AngioDynamics+gets+FDA+approval+to+study+NanoKnife+for+BPH+treatment/26657354.html <p>AngioDynamics, Inc. (NASDAQ: ANGO) announced that the U.S. Food and Drug Administration has approved its Investigational Device Exemption application to begin the RELIEF feasibility study, which will evaluate the company's NanoKnife System as a treatment for lower urinary tract symptoms in men with benign prostatic hyperplasia (BPH).</p><p>The NanoKnife System uses irreversible electroporation (IRE), a non-thermal ablation technology that delivers high-voltage electrical pulses to destroy targeted tissue. The device is currently cleared in the United States for the surgical ablation of soft tissue, including prostate tissue, but its use for BPH remains investigational.</p><p>The RELIEF study is a prospective, single-arm trial that http://www.streetinsider.com/FDA/AngioDynamics+gets+FDA+approval+to+study+NanoKnife+for+BPH+treatment/26657354.html Wed, 17 Jun 2026 08:32:21 -0400 ANGO http://www.streetinsider.com/Press+Releases/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html <p class="bwalignc"> Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the http://www.streetinsider.com/Press+Releases/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html Wed, 17 Jun 2026 08:30:00 -0400 A.06822034 A.32727947 ANGO O.00048394 O.00056796 O.20026344 http://www.streetinsider.com/Press+Releases/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html <p class="bwalignc"> Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the http://www.streetinsider.com/Press+Releases/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html Wed, 17 Jun 2026 08:30:00 -0400 A.06822034 A.32727947 ANGO O.00048394 O.00056796 O.20026344 http://www.streetinsider.com/Press+Releases/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html <p class="bwalignc"> Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the http://www.streetinsider.com/Press+Releases/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html Wed, 17 Jun 2026 08:30:00 -0400 A.06822034 A.32727947 ANGO O.00048394 O.00056796 O.20026344 http://www.streetinsider.com/Press+Releases/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html <p class="bwalignc"> Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the http://www.streetinsider.com/Press+Releases/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html Wed, 17 Jun 2026 08:30:00 -0400 A.06822034 A.32727947 ANGO O.00048394 O.00056796 O.20026344 http://www.streetinsider.com/Press+Releases/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html <p class="bwalignc"> Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the http://www.streetinsider.com/Press+Releases/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html Wed, 17 Jun 2026 08:30:00 -0400 A.06822034 A.32727947 ANGO O.00048394 O.00056796 O.20026344 http://www.streetinsider.com/Press+Releases/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html <p class="bwalignc"> Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the http://www.streetinsider.com/Press+Releases/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html Wed, 17 Jun 2026 08:30:00 -0400 A.06822034 A.32727947 ANGO O.00048394 O.00056796 O.20026344 http://www.streetinsider.com/Business+Wire/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html <p class="bwalignc"> Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the http://www.streetinsider.com/Business+Wire/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html Wed, 17 Jun 2026 08:30:00 -0400 A.06822034 A.32727947 ANGO O.00048394 O.00056796 O.20026344 http://www.streetinsider.com/Business+Wire/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html <p class="bwalignc"> Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the http://www.streetinsider.com/Business+Wire/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html Wed, 17 Jun 2026 08:30:00 -0400 A.06822034 A.32727947 ANGO O.00048394 O.00056796 O.20026344 http://www.streetinsider.com/Business+Wire/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html <p class="bwalignc"> Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the http://www.streetinsider.com/Business+Wire/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html Wed, 17 Jun 2026 08:30:00 -0400 A.06822034 A.32727947 ANGO O.00048394 O.00056796 O.20026344 http://www.streetinsider.com/Business+Wire/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html <p class="bwalignc"> Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the http://www.streetinsider.com/Business+Wire/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html Wed, 17 Jun 2026 08:30:00 -0400 A.06822034 A.32727947 ANGO O.00048394 O.00056796 O.20026344 http://www.streetinsider.com/Business+Wire/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html <p class="bwalignc"> Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the http://www.streetinsider.com/Business+Wire/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html Wed, 17 Jun 2026 08:30:00 -0400 A.06822034 A.32727947 ANGO O.00048394 O.00056796 O.20026344 http://www.streetinsider.com/Business+Wire/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html <p class="bwalignc"> Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, for the http://www.streetinsider.com/Business+Wire/AngioDynamics+Receives+FDA+IDE+Approval+for+RELIEF+Feasibility+Study+Evaluating+NanoKnife+IRE+Platform+as+Minimally+Invasive+Treatment+for+Benign+Prostatic+Hyperplasia+%28BPH%29/26657309.html Wed, 17 Jun 2026 08:30:00 -0400 A.06822034 A.32727947 ANGO O.00048394 O.00056796 O.20026344 http://www.streetinsider.com/Press+Releases/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html <p class="bwalignc"> Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, in two clinical indications: http://www.streetinsider.com/Press+Releases/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html Thu, 28 May 2026 13:25:00 -0400 A.04529854 A.21855783 ANGO O.00056796 O.20520259 O.23924816 http://www.streetinsider.com/Press+Releases/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html <p class="bwalignc"> Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, in two clinical indications: http://www.streetinsider.com/Press+Releases/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html Thu, 28 May 2026 13:25:00 -0400 A.04529854 A.21855783 ANGO O.00056796 O.20520259 O.23924816 http://www.streetinsider.com/Press+Releases/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html <p class="bwalignc"> Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, in two clinical indications: http://www.streetinsider.com/Press+Releases/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html Thu, 28 May 2026 13:25:00 -0400 A.04529854 A.21855783 ANGO O.00056796 O.20520259 O.23924816 http://www.streetinsider.com/Press+Releases/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html <p class="bwalignc"> Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, in two clinical indications: http://www.streetinsider.com/Press+Releases/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html Thu, 28 May 2026 13:25:00 -0400 A.04529854 A.21855783 ANGO O.00056796 O.20520259 O.23924816 http://www.streetinsider.com/Press+Releases/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html <p class="bwalignc"> Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, in two clinical indications: http://www.streetinsider.com/Press+Releases/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html Thu, 28 May 2026 13:25:00 -0400 A.04529854 A.21855783 ANGO O.00056796 O.20520259 O.23924816 http://www.streetinsider.com/Press+Releases/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html <p class="bwalignc"> Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, in two clinical indications: http://www.streetinsider.com/Press+Releases/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html Thu, 28 May 2026 13:25:00 -0400 A.04529854 A.21855783 ANGO O.00056796 O.20520259 O.23924816 http://www.streetinsider.com/Business+Wire/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html <p class="bwalignc"> Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, in two clinical indications: http://www.streetinsider.com/Business+Wire/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html Thu, 28 May 2026 13:25:00 -0400 A.04529854 A.21855783 ANGO O.00056796 O.20520259 O.23924816 http://www.streetinsider.com/Business+Wire/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html <p class="bwalignc"> Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, in two clinical indications: http://www.streetinsider.com/Business+Wire/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html Thu, 28 May 2026 13:25:00 -0400 A.04529854 A.21855783 ANGO O.00056796 O.20520259 O.23924816 http://www.streetinsider.com/Business+Wire/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html <p class="bwalignc"> Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, in two clinical indications: http://www.streetinsider.com/Business+Wire/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html Thu, 28 May 2026 13:25:00 -0400 A.04529854 A.21855783 ANGO O.00056796 O.20520259 O.23924816 http://www.streetinsider.com/Business+Wire/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html <p class="bwalignc"> Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, in two clinical indications: http://www.streetinsider.com/Business+Wire/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html Thu, 28 May 2026 13:25:00 -0400 A.04529854 A.21855783 ANGO O.00056796 O.20520259 O.23924816 http://www.streetinsider.com/Business+Wire/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html <p class="bwalignc"> Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage </p> <p> LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, in two clinical indications: http://www.streetinsider.com/Business+Wire/AngioDynamics+Expands+Patient+Access+to+NanoKnife+IRE+for+Prostate+and+Liver+Cancer+as+Medicare+Coverage+Framework+Takes+Effect/26564867.html Thu, 28 May 2026 13:25:00 -0400 A.04529854 A.21855783 ANGO O.00056796 O.20520259 O.23924816